Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8563844 | 0.93 | AGTR2 (0.53) | AGTR2AGTR1 | |
| SCHEMBL9847882 | 0.92 | AGTR1 (0.48) | AGTR2AGTR1 | |
| SCHEMBL8566867 | 0.91 | AGTR2 (0.54) | AGTR2AGTR1 | |
| SCHEMBL8566359 | 0.88 | AGTR1 (0.54) | AGTR2AGTR1 | |
| L-158809 SCHEMBL683357 | 0.87 | AGTR2 (0.71) | AGTR2AGTR1 | |
| SCHEMBL9310177 | 0.87 | AGTR2 (0.43) | AGTR2AGTR1 | |
| L-158809 SCHEMBL7944169 | 0.86 | AGTR2 (0.70) | AGTR2AGTR1 | |
| SCHEMBL8972219 | 0.85 | AGTR1 (0.72) | AGTR2AGTR1 | |
| SCHEMBL9847847 | 0.85 | AGTR1 (0.47) | AGTR2AGTR1 | |
| SCHEMBL9406686 | 0.84 | AGTR1 (0.73) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0598702-B1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | EISAI CO LTD (JP) | 1998-06-10 | — | — | EP | claimed |
| EP-0598702-A1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | Eisai Co., Ltd. (JP) | 1994-05-25 | — | — | EP | claimed |
| EP-0420237-A1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | Eisai Co., Ltd. (JP) | 1991-04-03 | — | — | EP | claimed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-0598702-B1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | EISAI CO LTD (JP) | 1998-06-10 | — | — | EP | disclosed |
| US-5506238-A | HYPOTENSIVE AGENT | EISAI CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0628557-A1 | Biphenylmethane derivatives, the use of them and pharmacological compositions containing same | Eisai Co., Ltd. (JP) | 1994-12-14 | — | — | EP | disclosed |
| US-5328911-A | Cardiovascular disorders, hypotensive agents and congestive heart failure | EISAI CO., LTD. (JP) | 1994-07-12 | — | — | US | disclosed |
| EP-0598702-A1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | Eisai Co., Ltd. (JP) | 1994-05-25 | — | — | EP | disclosed |
| US-5298518-A | Biphenylmethane derivative and pharmacological use | EISAI CO., LTD. (JP) | 1994-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | AGTR2 2610/4885AGTR1 3252/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | AGTR2 9/4885AGTR1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.